|Awarded On||February 21, 2018|
|Title||Targeting the metastatic sarcoma niche using leukocyte biomimetic nanoparticles|
|Award Mechanism||Individual Investigator Research Awards for Cancer in Children and Adolescents|
|Institution/Organization||The Methodist Hospital Research Institute|
|Principal Investigator/Program Director||Ennio Tasciotti|
|Cancer Sites||Bone, Sarcoma|
Osteosarcoma (OS) is the most common bone tumor in the pediatric population. Patients that present or develop disseminated or metastatic disease have extremely poor survival rates. OS metastasizes via the blood stream and most frequently develops lesions in the lungs. The poor survival rates associated with a metastatic disease are a clear indication that present therapies are ineffective. Our proposed technology aims to revolutionize the current treatment of metastatic OS by developing therapies that are more effective, less toxic, and target the key pathways that govern the growth and progression of the metastatic OS cells. We will accomplish this by capturing therapeutics within a nanopar...